Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to 2342.13%.

  • Addex Therapeutics' EBIT Margin fell 11864200.0% to 2342.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 4217.87%, marking a year-over-year decrease of 34010700.0%. This contributed to the annual value of 681.82% for FY2024, which is 5427600.0% down from last year.
  • As of Q3 2025, Addex Therapeutics' EBIT Margin stood at 2342.13%, which was down 11864200.0% from 12575.46% recorded in Q2 2025.
  • Addex Therapeutics' 5-year EBIT Margin high stood at 12575.46% for Q2 2025, and its period low was 182692.31% during Q4 2024.
  • Its 4-year average for EBIT Margin is 12534.09%, with a median of 1017.78% in 2022.
  • In the last 5 years, Addex Therapeutics' EBIT Margin crashed by -1812306000bps in 2024 and then surged by 133574800bps in 2025.
  • Addex Therapeutics' EBIT Margin (Quarter) stood at 3463.7% in 2022, then skyrocketed by 58bps to 1461.7% in 2023, then plummeted by -12399bps to 182692.31% in 2024, then soared by 99bps to 2342.13% in 2025.
  • Its EBIT Margin stands at 2342.13% for Q3 2025, versus 12575.46% for Q2 2025 and 672.09% for Q1 2025.